Thorough understanding of the HO-1-mediated signaling pathways that control membrane-bound CD163 expression will be useful in developing novel therapeutic approaches to treat hemolysis-induced tissue injury in SCD and other hemolytic diseases. This evidence concerns the gene HMOX1 and Schnyder corneal dystrophy.